Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence
•Probiotics reduce markers of peripheral inflammation in PD.•Preclinical evidence suggests neuroprotective properties of probiotics in PD.•Probiotics activate the GLP-1 and PPAR-γ pathway in PD.•Future research should further explore the effects of probiotics on neuropsychiatric aspects of PD. There...
Uložené v:
| Vydané v: | Brain, behavior, and immunity Ročník 98; s. 59 - 73 |
|---|---|
| Hlavní autori: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier Inc
01.11.2021
|
| Predmet: | |
| ISSN: | 0889-1591, 1090-2139, 1090-2139 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | •Probiotics reduce markers of peripheral inflammation in PD.•Preclinical evidence suggests neuroprotective properties of probiotics in PD.•Probiotics activate the GLP-1 and PPAR-γ pathway in PD.•Future research should further explore the effects of probiotics on neuropsychiatric aspects of PD.
There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson’s disease (PD) and on the use of probiotics as a therapeutic strategy for this neurodegenerative disorder. While several studies have been published on the topic in recent years, there is still a lack of a comprehensive understanding of the effects of probiotics in PD and their possible underlying mechanisms. Through this systematic review, we collected a total of 17 articles, consisting of preclinical and clinical models of PD investigating the effect of probiotics on (1) energy metabolism, (2) inflammation and oxidative stress, (3) neurodegeneration, as well as (4) motor and (5) non-motor function. Articles were obtained from PubMed/Medline, Scopus, Web of Science and Embase databases. Findings from preclinical studies suggest that treatment with probiotics increases glucose metabolism (increased secretion of glucagon-like peptide-1), reduces peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduces peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreases neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons and levels of brain-derived neurotrophic factor), increases motor function (increased motor agility) and non-motor function (decreased memory deficits). Similarly, findings from clinical studies suggest that probiotics increase glucose metabolism (reduced insulin resistance), reduce peripheral inflammation (reduced peripheral TNF-α expression and C-reactive protein levels), and increase motor and non-motor function (decreased overall PD symptomatology and constipation); however, findings on oxidative stress were inconclusive across studies. Overall, this review is the first one to systematically report evidence for the putative beneficial effects of probiotics on molecular and cellular mechanisms, as well as behavioural phenotypes, in either preclinical or clinical studies in PD. However, additional and more robust studies are still needed to confirm these outcomes, and should aim to focus more on bench-to-bedside approaches, in order to address the existing gaps between preclinical and clinical findings in this field. |
|---|---|
| AbstractList | •Probiotics reduce markers of peripheral inflammation in PD.•Preclinical evidence suggests neuroprotective properties of probiotics in PD.•Probiotics activate the GLP-1 and PPAR-γ pathway in PD.•Future research should further explore the effects of probiotics on neuropsychiatric aspects of PD.
There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson’s disease (PD) and on the use of probiotics as a therapeutic strategy for this neurodegenerative disorder. While several studies have been published on the topic in recent years, there is still a lack of a comprehensive understanding of the effects of probiotics in PD and their possible underlying mechanisms. Through this systematic review, we collected a total of 17 articles, consisting of preclinical and clinical models of PD investigating the effect of probiotics on (1) energy metabolism, (2) inflammation and oxidative stress, (3) neurodegeneration, as well as (4) motor and (5) non-motor function. Articles were obtained from PubMed/Medline, Scopus, Web of Science and Embase databases. Findings from preclinical studies suggest that treatment with probiotics increases glucose metabolism (increased secretion of glucagon-like peptide-1), reduces peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduces peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreases neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons and levels of brain-derived neurotrophic factor), increases motor function (increased motor agility) and non-motor function (decreased memory deficits). Similarly, findings from clinical studies suggest that probiotics increase glucose metabolism (reduced insulin resistance), reduce peripheral inflammation (reduced peripheral TNF-α expression and C-reactive protein levels), and increase motor and non-motor function (decreased overall PD symptomatology and constipation); however, findings on oxidative stress were inconclusive across studies. Overall, this review is the first one to systematically report evidence for the putative beneficial effects of probiotics on molecular and cellular mechanisms, as well as behavioural phenotypes, in either preclinical or clinical studies in PD. However, additional and more robust studies are still needed to confirm these outcomes, and should aim to focus more on bench-to-bedside approaches, in order to address the existing gaps between preclinical and clinical findings in this field. There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson's disease (PD) and on the use of probiotics as a therapeutic strategy for this neurodegenerative disorder. While several studies have been published on the topic in recent years, there is still a lack of a comprehensive understanding of the effects of probiotics in PD and their possible underlying mechanisms. Through this systematic review, we collected a total of 17 articles, consisting of preclinical and clinical models of PD investigating the effect of probiotics on (1) energy metabolism, (2) inflammation and oxidative stress, (3) neurodegeneration, as well as (4) motor and (5) non-motor function. Articles were obtained from PubMed/Medline, Scopus, Web of Science and Embase databases. Findings from preclinical studies suggest that treatment with probiotics increases glucose metabolism (increased secretion of glucagon-like peptide-1), reduces peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduces peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreases neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons and levels of brain-derived neurotrophic factor), increases motor function (increased motor agility) and non-motor function (decreased memory deficits). Similarly, findings from clinical studies suggest that probiotics increase glucose metabolism (reduced insulin resistance), reduce peripheral inflammation (reduced peripheral TNF-α expression and C-reactive protein levels), and increase motor and non-motor function (decreased overall PD symptomatology and constipation); however, findings on oxidative stress were inconclusive across studies. Overall, this review is the first one to systematically report evidence for the putative beneficial effects of probiotics on molecular and cellular mechanisms, as well as behavioural phenotypes, in either preclinical or clinical studies in PD. However, additional and more robust studies are still needed to confirm these outcomes, and should aim to focus more on bench-to-bedside approaches, in order to address the existing gaps between preclinical and clinical findings in this field. There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson's disease (PD) and on the use of probiotics as a therapeutic strategy for this neurodegenerative disorder. While several studies have been published on the topic in recent years, there is still a lack of a comprehensive understanding of the effects of probiotics in PD and their possible underlying mechanisms. Through this systematic review, we collected a total of 17 articles, consisting of preclinical and clinical models of PD investigating the effect of probiotics on (1) energy metabolism, (2) inflammation and oxidative stress, (3) neurodegeneration, as well as (4) motor and (5) non-motor function. Articles were obtained from PubMed/Medline, Scopus, Web of Science and Embase databases. Findings from preclinical studies suggest that treatment with probiotics increases glucose metabolism (increased secretion of glucagon-like peptide-1), reduces peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduces peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreases neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons and levels of brain-derived neurotrophic factor), increases motor function (increased motor agility) and non-motor function (decreased memory deficits). Similarly, findings from clinical studies suggest that probiotics increase glucose metabolism (reduced insulin resistance), reduce peripheral inflammation (reduced peripheral TNF-α expression and C-reactive protein levels), and increase motor and non-motor function (decreased overall PD symptomatology and constipation); however, findings on oxidative stress were inconclusive across studies. Overall, this review is the first one to systematically report evidence for the putative beneficial effects of probiotics on molecular and cellular mechanisms, as well as behavioural phenotypes, in either preclinical or clinical studies in PD. However, additional and more robust studies are still needed to confirm these outcomes, and should aim to focus more on bench-to-bedside approaches, in order to address the existing gaps between preclinical and clinical findings in this field.There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson's disease (PD) and on the use of probiotics as a therapeutic strategy for this neurodegenerative disorder. While several studies have been published on the topic in recent years, there is still a lack of a comprehensive understanding of the effects of probiotics in PD and their possible underlying mechanisms. Through this systematic review, we collected a total of 17 articles, consisting of preclinical and clinical models of PD investigating the effect of probiotics on (1) energy metabolism, (2) inflammation and oxidative stress, (3) neurodegeneration, as well as (4) motor and (5) non-motor function. Articles were obtained from PubMed/Medline, Scopus, Web of Science and Embase databases. Findings from preclinical studies suggest that treatment with probiotics increases glucose metabolism (increased secretion of glucagon-like peptide-1), reduces peripheral and central inflammation (reduced interleukin-6 and tumor necrosis factor-α (TNF-α)), reduces peripheral and central oxidative stress (reduced peripheral superoxide anion levels and increased central antioxidant glutathione levels), decreases neurodegeneration (increased numbers of tyrosine hydroxylase dopaminergic neurons and levels of brain-derived neurotrophic factor), increases motor function (increased motor agility) and non-motor function (decreased memory deficits). Similarly, findings from clinical studies suggest that probiotics increase glucose metabolism (reduced insulin resistance), reduce peripheral inflammation (reduced peripheral TNF-α expression and C-reactive protein levels), and increase motor and non-motor function (decreased overall PD symptomatology and constipation); however, findings on oxidative stress were inconclusive across studies. Overall, this review is the first one to systematically report evidence for the putative beneficial effects of probiotics on molecular and cellular mechanisms, as well as behavioural phenotypes, in either preclinical or clinical studies in PD. However, additional and more robust studies are still needed to confirm these outcomes, and should aim to focus more on bench-to-bedside approaches, in order to address the existing gaps between preclinical and clinical findings in this field. |
| Author | Leta, Valentina Chung-Faye, Guy Borsini, Alessandra Pariante, Carmine M. Milner, Oliver Metta, Vinod Ray Chaudhuri, K. |
| Author_xml | – sequence: 1 givenname: Valentina surname: Leta fullname: Leta, Valentina email: valentina.1.leta@kcl.ac.uk organization: King’s College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London SE5 8AF, UK – sequence: 2 givenname: K. surname: Ray Chaudhuri fullname: Ray Chaudhuri, K. organization: King’s College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London SE5 8AF, UK – sequence: 3 givenname: Oliver surname: Milner fullname: Milner, Oliver organization: King’s College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London SE5 8AF, UK – sequence: 4 givenname: Guy surname: Chung-Faye fullname: Chung-Faye, Guy organization: Department of Gastroenterology, King’s College Hospital, London, UK – sequence: 5 givenname: Vinod surname: Metta fullname: Metta, Vinod organization: Parkinson’s Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London SE5 9RS, UK – sequence: 6 givenname: Carmine M. surname: Pariante fullname: Pariante, Carmine M. organization: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK – sequence: 7 givenname: Alessandra surname: Borsini fullname: Borsini, Alessandra email: alessandra.borsini@kcl.ac.uk organization: National Institute for Health Research (NIHR), Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34364965$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFuFSEYhYmpsbfVB3BjWLqZEZiBGXTVNGpNGnWha8LAj-F2Bipwa-7OrY_g6_kk5Xp7XXRRF4RAznf-_OecoKMQAyD0nJKWEiperdtp8i0jjLZkaAkTj9CKEkkaRjt5hFZkHGVDuaTH6CTnNSGEd3R8go67vhO9FHyFfn2ETYrfIHiDdbD1FN_44Ga9LLrEtMXgHJiScXT4OsXJx-JNxj7gzzpd-ZBj-PPzd8bWZ9AZXuMznLe5QKWrZYIbDz_2LJjZ1zF6_jvo36MqLAQDT9Fjp-cMz-7uU_T13dsv5xfN5af3H87PLhvTk640WnLgAJzRkQ5gjNQ9WGG4FNb0tme9nRzTmg2M69H1zgAx9dN1wDh3znWn6OXet27zfQO5qMVnA_OsA8RNVlUmhZBUiCp9cSfdTAtYdZ38otNWHeKrgmEvMCnmnMAp40tdPIaStJ8VJWpXlFqrWpTaFaXIoGpRlaT3yIP5Q8ybPQM1npprUtn4XXTW13CLstE_SMt79KGCK9j-h70FKKbCbQ |
| CitedBy_id | crossref_primary_10_1007_s12602_025_10501_w crossref_primary_10_3389_fnagi_2025_1468895 crossref_primary_10_1016_j_neuropharm_2022_108959 crossref_primary_10_1111_ene_15734 crossref_primary_10_3390_nu15071737 crossref_primary_10_62329_ywtf3283 crossref_primary_10_1016_j_bbi_2025_106093 crossref_primary_10_1007_s00253_023_12789_6 crossref_primary_10_3390_ijms26010122 crossref_primary_10_1016_j_fbr_2023_100327 crossref_primary_10_21926_obm_neurobiol_2404254 crossref_primary_10_1016_j_clnesp_2023_02_025 crossref_primary_10_3390_ijms25031641 crossref_primary_10_1007_s12602_024_10433_x crossref_primary_10_1002_mdc3_13957 crossref_primary_10_1016_j_bbi_2021_10_015 crossref_primary_10_1038_s41598_024_60683_6 crossref_primary_10_1007_s40265_021_01664_1 crossref_primary_10_3390_brainsci14040358 crossref_primary_10_3389_fneur_2023_1185375 crossref_primary_10_3390_ijms26041773 crossref_primary_10_3389_fcimb_2024_1421270 crossref_primary_10_3389_fnins_2022_878239 crossref_primary_10_1007_s11064_025_04528_2 crossref_primary_10_1017_gmb_2023_4 crossref_primary_10_1186_s12967_025_06584_2 crossref_primary_10_3390_microorganisms10071428 crossref_primary_10_1111_1751_7915_14550 crossref_primary_10_1016_j_arr_2022_101834 crossref_primary_10_1016_j_ejphar_2024_176884 crossref_primary_10_3390_foods12183378 crossref_primary_10_3390_nu16244405 crossref_primary_10_1007_s00429_025_03003_6 crossref_primary_10_1007_s12602_025_10613_3 crossref_primary_10_3389_fneur_2023_1046910 crossref_primary_10_3390_nu15061436 crossref_primary_10_3389_fneur_2023_1174698 crossref_primary_10_3389_fnut_2024_1446854 crossref_primary_10_3390_ijms25053010 crossref_primary_10_1002_mdc3_13786 crossref_primary_10_1039_D2FO03825K crossref_primary_10_3390_life13051124 crossref_primary_10_1016_j_brainres_2025_149925 crossref_primary_10_3389_fcimb_2022_1038928 crossref_primary_10_3389_fmicb_2024_1328324 crossref_primary_10_1016_j_jfma_2022_09_010 |
| Cites_doi | 10.1186/1742-2094-3-5 10.1093/ijnp/pyx083 10.3389/fendo.2020.00025 10.3945/an.116.014407 10.18632/aging.102927 10.1002/mds.27105 10.1053/j.gastro.2014.01.052 10.1038/nrn.2017.62 10.1073/pnas.0509567103 10.1016/j.jnutbio.2019.03.021 10.1002/mds.28119 10.3233/JPD-191711 10.1136/jnnp.55.3.181 10.1016/j.pneurobio.2016.10.001 10.1016/S0140-6736(14)61393-3 10.1101/2020.08.10.20171397 10.1016/j.celrep.2019.12.078 10.1016/j.bja.2019.07.026 10.1038/nrneurol.2017.27 10.1371/journal.pmed.1000097 10.3390/microorganisms8111661 10.1016/j.parkreldis.2016.08.019 10.1016/j.neubiorev.2020.12.026 10.1111/jnc.14928 10.3233/JPD-171192 10.1007/s40265-015-0420-z 10.3389/fnins.2019.00328 10.1038/nature22815 10.3233/JPD-212570 10.1002/mds.26069 10.3389/fimmu.2019.00969 10.1016/j.neurobiolaging.2013.11.001 10.1038/s41531-020-0112-6 10.1186/1471-2288-14-43 10.1016/j.bbi.2017.05.006 10.2147/CIA.S106284 10.1016/bs.pbr.2020.01.004 10.1007/s11274-020-02879-2 10.1016/j.bbi.2020.07.036 10.3390/brainsci10040206 10.1080/07315724.2018.1487346 10.1038/nrneurol.2015.197 10.1007/s12272-018-1063-x 10.7717/peerj.10125 10.1016/j.clnu.2018.05.018 10.1038/s41579-020-00460-0 10.1136/gut.46.2.218 10.1212/WNL.0000000000003127 10.1016/j.nut.2020.110995 10.1016/j.jclinepi.2009.06.006 10.3945/ajcn.114.089151 10.3390/nu9091021 10.3390/molecules25214891 10.3390/nu11040890 10.3390/ijms20205068 10.1016/j.bbi.2020.10.014 10.1002/mds.25736 10.1186/s12974-020-02062-2 10.1002/mds.26424 10.1002/mds.27602 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Inc. Copyright © 2021 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2021 Elsevier Inc. – notice: Copyright © 2021 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bbi.2021.07.026 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1090-2139 |
| EndPage | 73 |
| ExternalDocumentID | 34364965 10_1016_j_bbi_2021_07_026 S0889159121002907 |
| Genre | Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G108/603 – fundername: Medical Research Council grantid: MR/N029488/1 |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM 9JO AAAJQ AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABOYX ABWVN ABXDB ACDAQ ACGFO ACGFS ACLOT ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HMQ HVGLF HZ~ IHE J1W KOM L7B LG5 LUGTX LZ5 M2U M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SIN SNS SPCBC SSB SSI SSN SSY SSZ T5K TN5 UAP UNMZH UPT WUQ XPP XSW Z5R ZGI ZMT ~G- ~HD ~S- AACTN AADPK AAIAV ABYKQ AFKWA AFYLN AJBFU AJOXV AMFUW RIG 9DU AAYXX CITATION AFCTW AGCQF AGRNS BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 |
| ID | FETCH-LOGICAL-c403t-a95e5ee521817ecc9a4ed6c596dc4d424dbf2aa2725a8f4fce0c24df3e255fff3 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000706632500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0889-1591 1090-2139 |
| IngestDate | Sat Sep 27 19:38:33 EDT 2025 Mon Jul 21 06:06:20 EDT 2025 Tue Nov 18 22:32:15 EST 2025 Sat Nov 29 07:10:35 EST 2025 Fri Feb 23 02:42:31 EST 2024 Tue Oct 14 19:24:30 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | CRP GLP-1 BDNF Non-motor symptoms Inflammation Iba1 Metabolism IL-6 PPARγ GFAP Probiotics TH TNF-α Neurodegeneration SN GSH Parkinson’s disease Motor symptoms |
| Language | English |
| License | Copyright © 2021 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c403t-a95e5ee521817ecc9a4ed6c596dc4d424dbf2aa2725a8f4fce0c24df3e255fff3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 34364965 |
| PQID | 2559669166 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_2559669166 pubmed_primary_34364965 crossref_citationtrail_10_1016_j_bbi_2021_07_026 crossref_primary_10_1016_j_bbi_2021_07_026 elsevier_sciencedirect_doi_10_1016_j_bbi_2021_07_026 elsevier_clinicalkey_doi_10_1016_j_bbi_2021_07_026 |
| PublicationCentury | 2000 |
| PublicationDate | November 2021 2021-11-00 20211101 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: November 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Brain, behavior, and immunity |
| PublicationTitleAlternate | Brain Behav Immun |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Borsini, Di Benedetto, Giacobbe, Pariante (b0060) 2020; 21 Moher, Liberati, Tetzlaff, Altman (b0220) 2009; 6 Unger, Spiegel, Dillmann, Grundmann, Philippeit, Bürmann, Faßbender, Schwiertz, Schäfer (b0325) 2016; 32 Houser, Tansey (b0140) 2017; 3 Nishiwaki, Ito, Ishida, Hamaguchi, Maeda, Kashihara, Tsuboi, Ueyama, Shimamura, Mori, Kurokawa, Katsuno, Hirayama, Ohno (b0230) 2020; 35 Borsini, A., A. Cattaneo, C. Malpighi, S. Thuret, N.A. Harrison, M.R.C.I. Consortium, P.A. Zunszain, C.M. Pariante. 2018. Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms. Int. J. Neuropsychopharmacol. 21:187-200. Silva, Bernardi, Frozza (b0285) 2020; 11 Griffin, Liu, Li, Mrak, Barger (b0115) 2006; 3 Tamtaji, Taghizadeh, Daneshvar Kakhaki, Kouchaki, Bahmani, Borzabadi, Oryan, Mafi, Asemi (b0315) 2019; 38 Aarsland, Creese, Politis, Chaudhuri, ffytche, Weintraub, Ballard (b0005) 2017; 13 Hughes, Daniel, Kilford, Lees (b0150) 1992; 55 Kalia, Lang (b0155) 2015; 386 Klingelhoefer, Reichmann (b0170) 2015; 11 Castelli, d’Angelo, Lombardi, Alfonsetti, Antonosante, Catanesi, Benedetti, Palumbo, Cifone, Giordano, Desideri, Cimini (b0075) 2020; 12 Magistrelli, Amoruso, Mogna, Graziano, Cantello, Pane, Comi (b0195) 2019; 10 Wallen, Appah, Dean, Sesler, Factor, Molho, Zabetian, Standaert, Payami (b0335) 2020; 6 Schapira, Chaudhuri, Jenner (b0260) 2017; 18 Leta, Urso, Batzu, Weintraub, Titova, Aarsland, Martinez-Martin, Borghammer, van Wamelen, Yousaf, Rizos, Rodriguez-Blazquez, Chung-Faye, Ray Chaudhuri (bib351) 2021; 11 Barcelo, Claustre, Moro, Chayvialle, Cuber, Plaisancié (b0030) 2000; 46 Dwyer, Chaiquin, Landrigan, Ayoub, Shail, Rocha, Childers, Storey, Philpott, Sun, Hayley (b0100) 2021; 18 Boertien, Pereira, Aho, Scheperjans, van Laar (b0045) 2019; 9 Dimidi, E., S. Christodoulides, K.C. Fragkos, S.M. Scott, and K. Whelan. 2014. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am. J Clin. Nutrit. 100:1075–1084. Lim, Bang, Choi (b0190) 2018; 41 Dimidi, Christodoulides, Scott, Whelan (b0090) 2017; 8 Hsieh, Kuo, Hsieh, Shieh, Peng, Chen, Chang, Huang, Chen, Chang, Chen, Chen (b0145) 2020; 10 Yang, Millischer, Rodin, MacFabe, Villaescusa, Lavebratt (b0350) 2020; 154 Mohammadi, Dargahi, Peymani, Mirzanejad, Alizadeh, Naserpour, Nassiri-Asl (b0215) 2019; 38 Hollister, Gao, Versalovic (b0130) 2014; 146 Bermúdez-Humarán, Salinas, Ortiz, Ramirez-Jirano, Morales, Bitzer-Quintero (b0040) 2019; 11 Venkatesan, Iyer, Narayanasamy, Siva, Vellingiri (b0330) 2020; 21 Markowiak, Śliżewska (b0200) 2017; 9 Sulzer, Alcalay, Garretti, Cote, Kanter, Agin-Liebes, Liong, McMurtrey, Hildebrand, Mao, Dawson, Dawson, Oseroff, Pham, Sidney, Dillon, Carpenter, Weiskopf, Phillips, Mallal, Peters, Frazier, Lindestam Arlehamn, Sette (b0300) 2017; 546 Sterne, Savović, Page, Elbers, Blencowe, Boutron, Cates, Cheng, Corbett, Eldridge, Emberson, Hernán, Hopewell, Hróbjartsson, Junqueira, Jüni, Kirkham, Lasserson, Li, McAleenan, Reeves, Shepperd, Shrier, Stewart, Tilling, White, Whiting, Higgins (b0295) 2019; 366 Marsova, Poluektova, Odorskaya, Ambaryan, Revishchin, Pavlova, Danilenko (b0205) 2020; 36 Perez Visñuk, D., G. Savoy de Giori, J.G. LeBlanc, and A. de Moreno de LeBlanc. 2020. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model. Nutrition (Burbank, Los Angeles County, Calif.). 79:110995. Hooijmans, Rovers, de Vries, Leenaars, Ritskes-Hoitinga, Langendam (b0135) 2014; 14 Romano, S., G.M. Savva, J.R. Bedarf, I.G. Charles, F. Hildebrand, and A. Narbad. 2020. Meta-analysis of the gut microbiome of Parkinson's disease patients suggests alterations linked to intestinal inflammation. medRxiv: 1397. d’Angelo, Castelli, Catanesi, Antonosante, Dominguez-Benot, Ippoliti, Benedetti, Cimini (b0080) 2019; 20 Srivastav, Neupane, Bhurtel, Katila, Maharjan, Choi, Hong, Choi (b0290) 2019; 69 Konnova, E.A., and M. Swanberg. 2018. Animal Models of Parkinson’s Disease. In Parkinson’s Disease: Pathogenesis and Clinical Aspects. T.B. Stoker and J.C. Greenland, editors. Codon Publications. Copyright: The Authors., Brisbane (AU). Goya, Xue, Sampedro-Torres-Quevedo, Arnaouteli, Riquelme-Dominguez, Romanowski, Brydon, Ball, Stanley-Wall, Doitsidou (b0110) 2020; 30 Liberati, Altman, Tetzlaff, Mulrow, Gøtzsche, Ioannidis, Clarke, Devereaux, Kleijnen, Moher (b0185) 2009; 62 Syed, McCormack (b0310) 2015; 75 Keshavarzian, Engen, Bonvegna, Cilia (b0165) 2020; 252 Scheperjans, Aho, Pereira, Koskinen, Paulin, Pekkonen, Haapaniemi, Kaakkola, Eerola‐Rautio, Pohja, Kinnunen, Murros, Auvinen (b0265) 2015; 30 Heintz-Buschart, Pandey, Wicke, Sixel-Döring, Janzen, Sittig-Wiegand, Trenkwalder, Oertel, Mollenhauer, Wilmes (b0125) 2018; 33 Liao, Cheng, You, Kuo, Huang, Chiou, Hsu, Hsieh-Li, Wang, Tsai (b0180) 2020; 90 Shahbazi, Yasavoli-Sharahi, Alsadi, Ismail, Matar (b0275) 2020; 25 Metta, Leta, Mrudula, Prashanth, Goyal, Borgohain, Chung-Faye, Chaudhuri (b0210) 2021 Seppi, Ray Chaudhuri, Coelho, Fox, Katzenschlager, Perez Lloret, Weintraub, Sampaio, Chahine, Hametner, Heim, Lim, Poewe, Djamshidian‐Tehrani (b0270) 2019; 34 Sun, Li, Jin, Yu, Mao, Su, Ling, Liu (b0305) 2020; 91 Borsini, Alboni, Horowitz, Tojo, Cannazza, Su, Pariante, Zunszain (b0050) 2017; 65 Xie, Prasad (b0340) 2020; 8 Purton, Staskova, Lane, Dawson, West, Firth, Clarke, Cryan, Berk, O’Neil, Dean, Hadi, Honan, Marx (b0245) 2021; 123 Xin, J., D. Zeng, H. Wang, N. Sun, A. Khalique, Y. Zhao, L. Wu, K. Pan, B. Jing, and X. Ni. 2020. Lactobacillus johnsonii BS15 improves intestinal environment against fluoride-induced memory impairment in mice-a study based on the gut-brain axis hypothesis. PeerJ. 8:1012. Kelly, Carvey, Keshavarzian, Shannon, Shaikh, Bakay, Kordower (b0160) 2014; 29 Morais, Schreiber, Mazmanian (b0225) 2021; 19 Tan, Lim, Chong, Azhan, Hor, Lim, Low, Chong, Mahadeva, Lang (b0320) 2020; 5 Barichella, Pacchetti, Bolliri, Cassani, Iorio, Pusani, Pinelli, Privitera, Cesari, Faierman, Caccialanza, Pezzoli, Cereda (b0035) 2016; 87 Alecu, Bennett (b0010) 2019; 13 Dunn, Allen, Mamais, Ling, Li, Duberley, Hargreaves, Pope, Holton, Lees, Heales, Bandopadhyay (b0095) 2014; 35 Postuma, Berg, Stern, Poewe, Olanow, Oertel, Obeso, Marek, Litvan, Lang, Halliday, Goetz, Gasser, Dubois, Chan, Bloem, Adler, Deuschl (b0240) 2015; 30 Cassani, Privitera, Pezzoli, Pusani, Madio, Iorio, Barichella (b0070) 2011; 57 Alipour Nosrani, Tamtaji, Alibolandi, Sarkar, Ghazanfari, Azami Tameh, Taghizadeh, Banikazemi, Hadavi, Naderi Taheri (b0015) 2020 Athauda, Foltynie (b0020) 2016; 145–146 Borzabadi, Oryan, Eidi, Aghadavod, Daneshvar Kakhaki, Tamtaji, Taghizadeh, Asemi (b0065) 2018; 21 Shults (b0280) 2006; 103 Guo, Chen, Xing, Liu (b0120) 2019; 123 Georgescu, Ancusa, Georgescu, Ionita, Reisz (b0105) 2016; 11 Athauda, Wyse, Brundin, Foltynie (b0025) 2017; 7 Rocha, de Miranda, Teixeira (b0250) 2015; 2015 Marsova (10.1016/j.bbi.2021.07.026_b0205) 2020; 36 Shults (10.1016/j.bbi.2021.07.026_b0280) 2006; 103 Leta (10.1016/j.bbi.2021.07.026_bib351) 2021; 11 Sterne (10.1016/j.bbi.2021.07.026_b0295) 2019; 366 Postuma (10.1016/j.bbi.2021.07.026_b0240) 2015; 30 Tan (10.1016/j.bbi.2021.07.026_b0320) 2020; 5 Moher (10.1016/j.bbi.2021.07.026_b0220) 2009; 6 Venkatesan (10.1016/j.bbi.2021.07.026_b0330) 2020; 21 Klingelhoefer (10.1016/j.bbi.2021.07.026_b0170) 2015; 11 Griffin (10.1016/j.bbi.2021.07.026_b0115) 2006; 3 Mohammadi (10.1016/j.bbi.2021.07.026_b0215) 2019; 38 Schapira (10.1016/j.bbi.2021.07.026_b0260) 2017; 18 Kalia (10.1016/j.bbi.2021.07.026_b0155) 2015; 386 Srivastav (10.1016/j.bbi.2021.07.026_b0290) 2019; 69 10.1016/j.bbi.2021.07.026_b0345 Barcelo (10.1016/j.bbi.2021.07.026_b0030) 2000; 46 Dunn (10.1016/j.bbi.2021.07.026_b0095) 2014; 35 d’Angelo (10.1016/j.bbi.2021.07.026_b0080) 2019; 20 Kelly (10.1016/j.bbi.2021.07.026_b0160) 2014; 29 Sun (10.1016/j.bbi.2021.07.026_b0305) 2020; 91 Sulzer (10.1016/j.bbi.2021.07.026_b0300) 2017; 546 Hollister (10.1016/j.bbi.2021.07.026_b0130) 2014; 146 Dimidi (10.1016/j.bbi.2021.07.026_b0090) 2017; 8 Liao (10.1016/j.bbi.2021.07.026_b0180) 2020; 90 Liberati (10.1016/j.bbi.2021.07.026_b0185) 2009; 62 Shahbazi (10.1016/j.bbi.2021.07.026_b0275) 2020; 25 Nishiwaki (10.1016/j.bbi.2021.07.026_b0230) 2020; 35 Silva (10.1016/j.bbi.2021.07.026_b0285) 2020; 11 Alecu (10.1016/j.bbi.2021.07.026_b0010) 2019; 13 Seppi (10.1016/j.bbi.2021.07.026_b0270) 2019; 34 Borzabadi (10.1016/j.bbi.2021.07.026_b0065) 2018; 21 Dwyer (10.1016/j.bbi.2021.07.026_b0100) 2021; 18 Magistrelli (10.1016/j.bbi.2021.07.026_b0195) 2019; 10 Morais (10.1016/j.bbi.2021.07.026_b0225) 2021; 19 Castelli (10.1016/j.bbi.2021.07.026_b0075) 2020; 12 Purton (10.1016/j.bbi.2021.07.026_b0245) 2021; 123 Lim (10.1016/j.bbi.2021.07.026_b0190) 2018; 41 Keshavarzian (10.1016/j.bbi.2021.07.026_b0165) 2020; 252 Rocha (10.1016/j.bbi.2021.07.026_b0250) 2015; 2015 10.1016/j.bbi.2021.07.026_b0175 Metta (10.1016/j.bbi.2021.07.026_b0210) 2021 Borsini (10.1016/j.bbi.2021.07.026_b0060) 2020; 21 Wallen (10.1016/j.bbi.2021.07.026_b0335) 2020; 6 10.1016/j.bbi.2021.07.026_b0055 Georgescu (10.1016/j.bbi.2021.07.026_b0105) 2016; 11 Athauda (10.1016/j.bbi.2021.07.026_b0020) 2016; 145–146 10.1016/j.bbi.2021.07.026_b0255 Hooijmans (10.1016/j.bbi.2021.07.026_b0135) 2014; 14 Borsini (10.1016/j.bbi.2021.07.026_b0050) 2017; 65 Syed (10.1016/j.bbi.2021.07.026_b0310) 2015; 75 Barichella (10.1016/j.bbi.2021.07.026_b0035) 2016; 87 Unger (10.1016/j.bbi.2021.07.026_b0325) 2016; 32 Tamtaji (10.1016/j.bbi.2021.07.026_b0315) 2019; 38 10.1016/j.bbi.2021.07.026_b0085 Heintz-Buschart (10.1016/j.bbi.2021.07.026_b0125) 2018; 33 Alipour Nosrani (10.1016/j.bbi.2021.07.026_b0015) 2020 Cassani (10.1016/j.bbi.2021.07.026_b0070) 2011; 57 Hughes (10.1016/j.bbi.2021.07.026_b0150) 1992; 55 Hsieh (10.1016/j.bbi.2021.07.026_b0145) 2020; 10 Boertien (10.1016/j.bbi.2021.07.026_b0045) 2019; 9 Bermúdez-Humarán (10.1016/j.bbi.2021.07.026_b0040) 2019; 11 Scheperjans (10.1016/j.bbi.2021.07.026_b0265) 2015; 30 Guo (10.1016/j.bbi.2021.07.026_b0120) 2019; 123 Athauda (10.1016/j.bbi.2021.07.026_b0025) 2017; 7 Xie (10.1016/j.bbi.2021.07.026_b0340) 2020; 8 Aarsland (10.1016/j.bbi.2021.07.026_b0005) 2017; 13 Markowiak (10.1016/j.bbi.2021.07.026_b0200) 2017; 9 Yang (10.1016/j.bbi.2021.07.026_b0350) 2020; 154 10.1016/j.bbi.2021.07.026_b0235 Houser (10.1016/j.bbi.2021.07.026_b0140) 2017; 3 Goya (10.1016/j.bbi.2021.07.026_b0110) 2020; 30 |
| References_xml | – volume: 57 start-page: 117 year: 2011 end-page: 121 ident: b0070 article-title: Use of probiotics for the treatment of constipation in Parkinson's disease patients publication-title: Minerva Gastroenterol. Dietol. – volume: 123 start-page: 1 year: 2021 end-page: 13 ident: b0245 article-title: Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: a systematic review and meta analysis publication-title: Neurosci. Biobehav. Rev. – volume: 8 start-page: 484 year: 2017 end-page: 494 ident: b0090 article-title: Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation publication-title: Adv Nutr. – volume: 3 start-page: 1 year: 2006 end-page: 9 ident: b0115 article-title: Interleukin-1 mediates Alzheimer and Lewy body pathologies publication-title: J. Neuroinflamm. – volume: 5 start-page: 772 year: 2020 end-page: 782 ident: b0320 article-title: Probiotics for constipation in Parkinson's disease: a randomized placebo-controlled study publication-title: Neurology – volume: 145–146 start-page: 98 year: 2016 end-page: 120 ident: b0020 article-title: Insulin resistance and Parkinson's disease: a new target for disease modification? publication-title: Prog. Neurobiol. – reference: Perez Visñuk, D., G. Savoy de Giori, J.G. LeBlanc, and A. de Moreno de LeBlanc. 2020. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model. Nutrition (Burbank, Los Angeles County, Calif.). 79:110995. – reference: Dimidi, E., S. Christodoulides, K.C. Fragkos, S.M. Scott, and K. Whelan. 2014. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am. J Clin. Nutrit. 100:1075–1084. – volume: 21 start-page: 187 year: 2020 end-page: 200 ident: b0060 article-title: Pro- and anti-inflammatory properties of interleukin (IL6) in vitro: relevance for major depression and for human hippocampal neurogenesis publication-title: Int. J. Neuropsychopharmacol. – volume: 90 start-page: 26 year: 2020 end-page: 46 ident: b0180 article-title: Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease publication-title: Brain Behav. Immun. – volume: 41 start-page: 943 year: 2018 end-page: 954 ident: b0190 article-title: Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease publication-title: Arch Pharm Res. – volume: 103 start-page: 1661 year: 2006 end-page: 1668 ident: b0280 article-title: Lewy bodies publication-title: PNAS – volume: 146 start-page: 1449 year: 2014 end-page: 1458 ident: b0130 article-title: Compositional and functional features of the gastrointestinal microbiome and their effects on human health publication-title: Gastroenterology – volume: 11 start-page: 25 year: 2020 ident: b0285 article-title: The role of short-chain fatty acids from gut microbiota in gut-brain communication publication-title: Front. Endocrinol. (Lausanne) – volume: 55 start-page: 181 year: 1992 end-page: 184 ident: b0150 article-title: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases publication-title: J. Neurol. Neurosurg. Psychiatry – reference: Xin, J., D. Zeng, H. Wang, N. Sun, A. Khalique, Y. Zhao, L. Wu, K. Pan, B. Jing, and X. Ni. 2020. Lactobacillus johnsonii BS15 improves intestinal environment against fluoride-induced memory impairment in mice-a study based on the gut-brain axis hypothesis. PeerJ. 8:1012. – volume: 12 start-page: 4641 year: 2020 end-page: 4659 ident: b0075 article-title: Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models publication-title: Aging – volume: 10 start-page: 206 year: 2020 ident: b0145 article-title: Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's Disease publication-title: Brain Sci. – volume: 30 start-page: 367 year: 2020 end-page: 380.e7 ident: b0110 article-title: Probiotic Bacillus subtilis protects against α-synuclein aggregation in C. elegans publication-title: Cell reports. – volume: 21 start-page: 100270 year: 2020 ident: b0330 article-title: Kynurenine pathway in Parkinson's disease-An update publication-title: Neurol. Sci. – volume: 18 start-page: 1 year: 2021 end-page: 15 ident: b0100 article-title: The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease publication-title: J. Neuroinflamm. – volume: 62 start-page: e1 year: 2009 end-page: e34 ident: b0185 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: J. Clin. Epidemiol. – volume: 10 start-page: 969 year: 2019 ident: b0195 article-title: Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence publication-title: Front. Immunol. – volume: 34 start-page: 180 year: 2019 end-page: 198 ident: b0270 article-title: Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review publication-title: Movem. Disorders – volume: 386 start-page: 896 year: 2015 end-page: 912 ident: b0155 article-title: Parkinson's disease publication-title: Lancet (London, England). – volume: 6 start-page: e1000097 year: 2009 ident: b0220 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med. – volume: 65 start-page: 230 year: 2017 end-page: 238 ident: b0050 article-title: Rescue of IL-1beta-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants publication-title: Brain Behav. Immun. – volume: 123 start-page: 637 year: 2019 end-page: 654 ident: b0120 article-title: Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential publication-title: Br. J. Anaesth. – volume: 30 start-page: 350 year: 2015 end-page: 358 ident: b0265 article-title: Gut microbiota are related to Parkinson's disease and clinical phenotype publication-title: Movem. Dis. – volume: 154 start-page: 635 year: 2020 end-page: 646 ident: b0350 article-title: Enteric short-chain fatty acids promote proliferation of human neural progenitor cells publication-title: J. Neurochem. – volume: 3 start-page: 1 year: 2017 end-page: 9 ident: b0140 article-title: The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? publication-title: npj Parkinson's Dis. – volume: 35 start-page: 1626 year: 2020 end-page: 1635 ident: b0230 article-title: Meta-analysis of gut dysbiosis in Parkinson's disease publication-title: Movem. Disord. – volume: 366 year: 2019 ident: b0295 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: BMJ (Clin. Res. ed.) – volume: 9 start-page: S297 year: 2019 end-page: S312 ident: b0045 article-title: Increasing comparability and utility of gut microbiome studies in Parkinson's disease: a systematic review publication-title: J. Parkinson's Dis. – volume: 35 start-page: 1111 year: 2014 end-page: 1115 ident: b0095 article-title: Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease publication-title: Neurobiol. Aging – reference: Konnova, E.A., and M. Swanberg. 2018. Animal Models of Parkinson’s Disease. In Parkinson’s Disease: Pathogenesis and Clinical Aspects. T.B. Stoker and J.C. Greenland, editors. Codon Publications. Copyright: The Authors., Brisbane (AU). – volume: 29 start-page: 999 year: 2014 end-page: 1009 ident: b0160 article-title: Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease publication-title: Movem. Dis. – volume: 18 start-page: 435 year: 2017 end-page: 450 ident: b0260 article-title: Non-motor features of Parkinson disease publication-title: Nat. Rev. Neurosci. – volume: 7 start-page: 451 year: 2017 end-page: 458 ident: b0025 article-title: Is exenatide a treatment for Parkinson's Disease? publication-title: J. Parkinson's Dis. – volume: 546 start-page: 656 year: 2017 end-page: 661 ident: b0300 article-title: T cells from patients with Parkinson's disease recognize α-synuclein peptides publication-title: Nature – volume: 69 start-page: 73 year: 2019 end-page: 86 ident: b0290 article-title: Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity publication-title: J. Nutrit. Biochem. – volume: 13 start-page: 328 year: 2019 ident: b0010 article-title: Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson's Disease publication-title: Front. Neurosci. – volume: 11 start-page: 1601 year: 2016 end-page: 1608 ident: b0105 article-title: Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope? publication-title: Clin. Interv. Aging – volume: 14 start-page: 1 year: 2014 end-page: 9 ident: b0135 article-title: SYRCLE's risk of bias tool for animal studies publication-title: BMC Med. Res. Method. – volume: 38 start-page: 1031 year: 2019 end-page: 1035 ident: b0315 article-title: Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial publication-title: Clin. Nutrit. – volume: 46 start-page: 218 year: 2000 end-page: 224 ident: b0030 article-title: Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon publication-title: Gut – volume: 19 start-page: 241 year: 2021 end-page: 255 ident: b0225 article-title: The gut microbiota-brain axis in behaviour and brain disorders publication-title: Nat Rev Microbiol. – volume: 33 start-page: 88 year: 2018 end-page: 98 ident: b0125 article-title: The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder publication-title: Movem. Disorders. – volume: 252 start-page: 357 year: 2020 end-page: 450 ident: b0165 article-title: The gut microbiome in Parkinson's disease: A culprit or a bystander? publication-title: Prog. Brain Res. – start-page: 1 year: 2020 end-page: 15 ident: b0015 article-title: Neuroprotective effects of probiotics bacteria on animal model of Parkinson's disease induced by 6-hydroxydopamine: a behavioral, biochemical, and histological study publication-title: J. Immunoassay Immunochem. – volume: 36 start-page: 1 year: 2020 end-page: 10 ident: b0205 article-title: Protective effects of Lactobacillus fermentum U-21 against paraquat-induced oxidative stress in Caenorhabditis elegans and mouse models publication-title: World J. Microbiol. Biotechnol. – reference: Borsini, A., A. Cattaneo, C. Malpighi, S. Thuret, N.A. Harrison, M.R.C.I. Consortium, P.A. Zunszain, C.M. Pariante. 2018. Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms. Int. J. Neuropsychopharmacol. 21:187-200. – volume: 11 start-page: 890 year: 2019 ident: b0040 article-title: From probiotics to psychobiotics: live beneficial bacteria which act on the brain-gut axis publication-title: Nutrients. – start-page: 1 year: 2021 end-page: 10 ident: b0210 article-title: Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation publication-title: J. Neurol. – volume: 38 start-page: 209 year: 2019 end-page: 217 ident: b0215 article-title: The effects of probiotic formulation pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a Lipopolysaccharide Rat Model publication-title: J. Am. Coll. Nutr. – volume: 2015 start-page: 1 year: 2015 end-page: 12 ident: b0250 article-title: Insights into neuroinflammation in Parkinson's disease: from biomarkers to anti-inflammatory based therapies publication-title: Biomed Res. Int. – reference: Romano, S., G.M. Savva, J.R. Bedarf, I.G. Charles, F. Hildebrand, and A. Narbad. 2020. Meta-analysis of the gut microbiome of Parkinson's disease patients suggests alterations linked to intestinal inflammation. medRxiv: 1397. – volume: 6 start-page: 11 year: 2020 end-page: 12 ident: b0335 article-title: Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens publication-title: npj Parkinson's Dis. – volume: 75 start-page: 1141 year: 2015 end-page: 1152 ident: b0310 article-title: Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus publication-title: Drugs – volume: 9 start-page: 1021 year: 2017 ident: b0200 article-title: Effects of probiotics, prebiotics, and synbiotics on human health publication-title: Nutrients – volume: 32 start-page: 66 year: 2016 end-page: 72 ident: b0325 article-title: Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls publication-title: Parkinsonism & Related Disorders – volume: 8 start-page: 1661 year: 2020 ident: b0340 article-title: Probiotics treatment improves hippocampal dependent cognition in a rodent model of Parkinson's Disease publication-title: Microorganisms. – volume: 25 start-page: 4891 year: 2020 ident: b0275 article-title: Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders publication-title: Molecules – volume: 11 start-page: 1209 year: 2021 end-page: 1219 ident: bib351 article-title: Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts publication-title: J Parkinsons Dis. – volume: 11 start-page: 625 year: 2015 end-page: 636 ident: b0170 article-title: Pathogenesis of Parkinson disease–the gut-brain axis and environmental factors publication-title: Nat. Rev. Neurol. – volume: 13 start-page: 217 year: 2017 end-page: 231 ident: b0005 article-title: Cognitive decline in Parkinson disease publication-title: Nat. Rev. Neurol. – volume: 87 start-page: 1274 year: 2016 end-page: 1280 ident: b0035 article-title: Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT publication-title: Neurology. – volume: 20 start-page: 5068 year: 2019 ident: b0080 article-title: PPARγ and cognitive performance publication-title: Int. J. Mol. Sci. – volume: 21 start-page: 289 year: 2018 end-page: 295 ident: b0065 article-title: The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's Disease: a randomized, double-blind PlaceboControlled Trial publication-title: Arch. Iranian Med. – volume: 30 start-page: 1591 year: 2015 end-page: 1601 ident: b0240 article-title: MDS clinical diagnostic criteria for Parkinson's disease publication-title: Movem. Disorders – volume: 91 start-page: 703 year: 2020 end-page: 715 ident: b0305 article-title: Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway publication-title: Brain Behav. Immun. – start-page: 1 year: 2021 ident: 10.1016/j.bbi.2021.07.026_b0210 article-title: Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation publication-title: J. Neurol. – volume: 3 start-page: 1 year: 2006 ident: 10.1016/j.bbi.2021.07.026_b0115 article-title: Interleukin-1 mediates Alzheimer and Lewy body pathologies publication-title: J. Neuroinflamm. doi: 10.1186/1742-2094-3-5 – volume: 366 issue: l4898 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0295 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: BMJ (Clin. Res. ed.) – ident: 10.1016/j.bbi.2021.07.026_b0055 doi: 10.1093/ijnp/pyx083 – volume: 11 start-page: 25 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0285 article-title: The role of short-chain fatty acids from gut microbiota in gut-brain communication publication-title: Front. Endocrinol. (Lausanne) doi: 10.3389/fendo.2020.00025 – volume: 8 start-page: 484 issue: 3 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0090 article-title: Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation publication-title: Adv Nutr. doi: 10.3945/an.116.014407 – volume: 12 start-page: 4641 issue: 5 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0075 article-title: Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models publication-title: Aging doi: 10.18632/aging.102927 – volume: 33 start-page: 88 issue: 1 year: 2018 ident: 10.1016/j.bbi.2021.07.026_b0125 article-title: The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder publication-title: Movem. Disorders. doi: 10.1002/mds.27105 – volume: 146 start-page: 1449 issue: 6 year: 2014 ident: 10.1016/j.bbi.2021.07.026_b0130 article-title: Compositional and functional features of the gastrointestinal microbiome and their effects on human health publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.01.052 – volume: 18 start-page: 435 issue: 7 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0260 article-title: Non-motor features of Parkinson disease publication-title: Nat. Rev. Neurosci. doi: 10.1038/nrn.2017.62 – volume: 103 start-page: 1661 issue: 6 year: 2006 ident: 10.1016/j.bbi.2021.07.026_b0280 article-title: Lewy bodies publication-title: PNAS doi: 10.1073/pnas.0509567103 – volume: 69 start-page: 73 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0290 article-title: Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity publication-title: J. Nutrit. Biochem. doi: 10.1016/j.jnutbio.2019.03.021 – volume: 35 start-page: 1626 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0230 article-title: Meta-analysis of gut dysbiosis in Parkinson's disease publication-title: Movem. Disord. doi: 10.1002/mds.28119 – volume: 9 start-page: S297 issue: s2 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0045 article-title: Increasing comparability and utility of gut microbiome studies in Parkinson's disease: a systematic review publication-title: J. Parkinson's Dis. doi: 10.3233/JPD-191711 – volume: 55 start-page: 181 issue: 3 year: 1992 ident: 10.1016/j.bbi.2021.07.026_b0150 article-title: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.55.3.181 – volume: 2015 start-page: 1 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0250 article-title: Insights into neuroinflammation in Parkinson's disease: from biomarkers to anti-inflammatory based therapies publication-title: Biomed Res. Int. – volume: 145–146 start-page: 98 year: 2016 ident: 10.1016/j.bbi.2021.07.026_b0020 article-title: Insulin resistance and Parkinson's disease: a new target for disease modification? publication-title: Prog. Neurobiol. doi: 10.1016/j.pneurobio.2016.10.001 – volume: 386 start-page: 896 issue: 9996 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0155 article-title: Parkinson's disease publication-title: Lancet (London, England). doi: 10.1016/S0140-6736(14)61393-3 – ident: 10.1016/j.bbi.2021.07.026_b0255 doi: 10.1101/2020.08.10.20171397 – volume: 57 start-page: 117 year: 2011 ident: 10.1016/j.bbi.2021.07.026_b0070 article-title: Use of probiotics for the treatment of constipation in Parkinson's disease patients publication-title: Minerva Gastroenterol. Dietol. – volume: 21 start-page: 289 year: 2018 ident: 10.1016/j.bbi.2021.07.026_b0065 article-title: The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's Disease: a randomized, double-blind PlaceboControlled Trial publication-title: Arch. Iranian Med. – volume: 30 start-page: 367 issue: 2 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0110 article-title: Probiotic Bacillus subtilis protects against α-synuclein aggregation in C. elegans publication-title: Cell reports. doi: 10.1016/j.celrep.2019.12.078 – volume: 123 start-page: 637 issue: 5 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0120 article-title: Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential publication-title: Br. J. Anaesth. doi: 10.1016/j.bja.2019.07.026 – volume: 13 start-page: 217 issue: 4 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0005 article-title: Cognitive decline in Parkinson disease publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2017.27 – volume: 6 start-page: e1000097 issue: 7 year: 2009 ident: 10.1016/j.bbi.2021.07.026_b0220 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med. doi: 10.1371/journal.pmed.1000097 – volume: 8 start-page: 1661 issue: 11 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0340 article-title: Probiotics treatment improves hippocampal dependent cognition in a rodent model of Parkinson's Disease publication-title: Microorganisms. doi: 10.3390/microorganisms8111661 – volume: 32 start-page: 66 year: 2016 ident: 10.1016/j.bbi.2021.07.026_b0325 article-title: Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls publication-title: Parkinsonism & Related Disorders doi: 10.1016/j.parkreldis.2016.08.019 – volume: 123 start-page: 1 year: 2021 ident: 10.1016/j.bbi.2021.07.026_b0245 article-title: Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: a systematic review and meta analysis publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2020.12.026 – volume: 154 start-page: 635 issue: 6 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0350 article-title: Enteric short-chain fatty acids promote proliferation of human neural progenitor cells publication-title: J. Neurochem. doi: 10.1111/jnc.14928 – volume: 7 start-page: 451 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0025 article-title: Is exenatide a treatment for Parkinson's Disease? publication-title: J. Parkinson's Dis. doi: 10.3233/JPD-171192 – volume: 75 start-page: 1141 issue: 10 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0310 article-title: Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus publication-title: Drugs doi: 10.1007/s40265-015-0420-z – volume: 21 start-page: 187 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0060 article-title: Pro- and anti-inflammatory properties of interleukin (IL6) in vitro: relevance for major depression and for human hippocampal neurogenesis publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyx083 – volume: 21 start-page: 100270 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0330 article-title: Kynurenine pathway in Parkinson's disease-An update publication-title: Neurol. Sci. – volume: 13 start-page: 328 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0010 article-title: Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson's Disease publication-title: Front. Neurosci. doi: 10.3389/fnins.2019.00328 – volume: 546 start-page: 656 issue: 7660 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0300 article-title: T cells from patients with Parkinson's disease recognize α-synuclein peptides publication-title: Nature doi: 10.1038/nature22815 – volume: 5 start-page: 772 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0320 article-title: Probiotics for constipation in Parkinson's disease: a randomized placebo-controlled study publication-title: Neurology – volume: 11 start-page: 1209 issue: 3 year: 2021 ident: 10.1016/j.bbi.2021.07.026_bib351 article-title: Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts publication-title: J Parkinsons Dis. doi: 10.3233/JPD-212570 – volume: 30 start-page: 350 issue: 3 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0265 article-title: Gut microbiota are related to Parkinson's disease and clinical phenotype publication-title: Movem. Dis. doi: 10.1002/mds.26069 – ident: 10.1016/j.bbi.2021.07.026_b0175 – volume: 3 start-page: 1 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0140 article-title: The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? publication-title: npj Parkinson's Dis. – volume: 10 start-page: 969 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0195 article-title: Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00969 – volume: 35 start-page: 1111 issue: 5 year: 2014 ident: 10.1016/j.bbi.2021.07.026_b0095 article-title: Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2013.11.001 – volume: 6 start-page: 11 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0335 article-title: Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens publication-title: npj Parkinson's Dis. doi: 10.1038/s41531-020-0112-6 – volume: 14 start-page: 1 year: 2014 ident: 10.1016/j.bbi.2021.07.026_b0135 article-title: SYRCLE's risk of bias tool for animal studies publication-title: BMC Med. Res. Method. doi: 10.1186/1471-2288-14-43 – volume: 65 start-page: 230 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0050 article-title: Rescue of IL-1beta-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2017.05.006 – volume: 11 start-page: 1601 year: 2016 ident: 10.1016/j.bbi.2021.07.026_b0105 article-title: Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope? publication-title: Clin. Interv. Aging doi: 10.2147/CIA.S106284 – volume: 252 start-page: 357 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0165 article-title: The gut microbiome in Parkinson's disease: A culprit or a bystander? publication-title: Prog. Brain Res. doi: 10.1016/bs.pbr.2020.01.004 – volume: 36 start-page: 1 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0205 article-title: Protective effects of Lactobacillus fermentum U-21 against paraquat-induced oxidative stress in Caenorhabditis elegans and mouse models publication-title: World J. Microbiol. Biotechnol. doi: 10.1007/s11274-020-02879-2 – volume: 90 start-page: 26 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0180 article-title: Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2020.07.036 – volume: 10 start-page: 206 issue: 4 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0145 article-title: Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's Disease publication-title: Brain Sci. doi: 10.3390/brainsci10040206 – volume: 38 start-page: 209 issue: 3 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0215 article-title: The effects of probiotic formulation pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a Lipopolysaccharide Rat Model publication-title: J. Am. Coll. Nutr. doi: 10.1080/07315724.2018.1487346 – volume: 11 start-page: 625 issue: 11 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0170 article-title: Pathogenesis of Parkinson disease–the gut-brain axis and environmental factors publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2015.197 – volume: 41 start-page: 943 issue: 10 year: 2018 ident: 10.1016/j.bbi.2021.07.026_b0190 article-title: Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease publication-title: Arch Pharm Res. doi: 10.1007/s12272-018-1063-x – ident: 10.1016/j.bbi.2021.07.026_b0345 doi: 10.7717/peerj.10125 – start-page: 1 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0015 article-title: Neuroprotective effects of probiotics bacteria on animal model of Parkinson's disease induced by 6-hydroxydopamine: a behavioral, biochemical, and histological study publication-title: J. Immunoassay Immunochem. – volume: 38 start-page: 1031 issue: 3 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0315 article-title: Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial publication-title: Clin. Nutrit. doi: 10.1016/j.clnu.2018.05.018 – volume: 19 start-page: 241 issue: 4 year: 2021 ident: 10.1016/j.bbi.2021.07.026_b0225 article-title: The gut microbiota-brain axis in behaviour and brain disorders publication-title: Nat Rev Microbiol. doi: 10.1038/s41579-020-00460-0 – volume: 46 start-page: 218 year: 2000 ident: 10.1016/j.bbi.2021.07.026_b0030 article-title: Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon publication-title: Gut doi: 10.1136/gut.46.2.218 – volume: 87 start-page: 1274 issue: 12 year: 2016 ident: 10.1016/j.bbi.2021.07.026_b0035 article-title: Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT publication-title: Neurology. doi: 10.1212/WNL.0000000000003127 – ident: 10.1016/j.bbi.2021.07.026_b0235 doi: 10.1016/j.nut.2020.110995 – volume: 62 start-page: e1 issue: 10 year: 2009 ident: 10.1016/j.bbi.2021.07.026_b0185 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: J. Clin. Epidemiol. doi: 10.1016/j.jclinepi.2009.06.006 – ident: 10.1016/j.bbi.2021.07.026_b0085 doi: 10.3945/ajcn.114.089151 – volume: 9 start-page: 1021 year: 2017 ident: 10.1016/j.bbi.2021.07.026_b0200 article-title: Effects of probiotics, prebiotics, and synbiotics on human health publication-title: Nutrients doi: 10.3390/nu9091021 – volume: 25 start-page: 4891 issue: 21 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0275 article-title: Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders publication-title: Molecules doi: 10.3390/molecules25214891 – volume: 11 start-page: 890 issue: 4 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0040 article-title: From probiotics to psychobiotics: live beneficial bacteria which act on the brain-gut axis publication-title: Nutrients. doi: 10.3390/nu11040890 – volume: 20 start-page: 5068 issue: 20 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0080 article-title: PPARγ and cognitive performance publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20205068 – volume: 91 start-page: 703 year: 2020 ident: 10.1016/j.bbi.2021.07.026_b0305 article-title: Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2020.10.014 – volume: 29 start-page: 999 issue: 8 year: 2014 ident: 10.1016/j.bbi.2021.07.026_b0160 article-title: Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease publication-title: Movem. Dis. doi: 10.1002/mds.25736 – volume: 18 start-page: 1 year: 2021 ident: 10.1016/j.bbi.2021.07.026_b0100 article-title: The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease publication-title: J. Neuroinflamm. doi: 10.1186/s12974-020-02062-2 – volume: 30 start-page: 1591 issue: 12 year: 2015 ident: 10.1016/j.bbi.2021.07.026_b0240 article-title: MDS clinical diagnostic criteria for Parkinson's disease publication-title: Movem. Disorders doi: 10.1002/mds.26424 – volume: 34 start-page: 180 issue: 2 year: 2019 ident: 10.1016/j.bbi.2021.07.026_b0270 article-title: Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review publication-title: Movem. Disorders doi: 10.1002/mds.27602 |
| SSID | ssj0005318 |
| Score | 2.5426414 |
| SecondaryResourceType | review_article |
| Snippet | •Probiotics reduce markers of peripheral inflammation in PD.•Preclinical evidence suggests neuroprotective properties of probiotics in PD.•Probiotics activate... There is increasing evidence highlighting the potential role of the gut-brain axis in the pathogenesis of Parkinson's disease (PD) and on the use of probiotics... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 59 |
| SubjectTerms | Anti-Inflammatory Agents - therapeutic use Brain-Gut Axis Dopaminergic Neurons Humans Inflammation Metabolism Motor symptoms Neurodegeneration Non-motor symptoms Parkinson Disease - drug therapy Parkinson’s disease Probiotics Probiotics - therapeutic use |
| Title | Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0889159121002907 https://dx.doi.org/10.1016/j.bbi.2021.07.026 https://www.ncbi.nlm.nih.gov/pubmed/34364965 https://www.proquest.com/docview/2559669166 |
| Volume | 98 |
| WOSCitedRecordID | wos000706632500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1090-2139 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005318 issn: 0889-1591 databaseCode: AIEXJ dateStart: 19950301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZKhxAvE2xcNmAyEuIBKVXrOBfzVqGN2xhIjKlvkZPYIlOXVr2M9Y1XfgK_hX_DL-H4mq7TxkXiJWrS2E57vvgcn8tnhJ7EJYtyULtBGSdhQFlBA7BCekFUcoATB6Wr2T6P9pODg3QwYB9arR-uFuZ0mNR1enbGxv9V1HANhK1KZ_9C3L5TuACfQehwBLHD8Y8Er-k24FtPxDqrAugXJH9iIupLKRxjzcKkmZormAy5cpyr7BCbAcGmLoBjCthXaZ-_mD6EL6_URXLuRNgNS8_FjSfckBY4egCXPVrpOpWZd_DvC2PWHnGlFu0e3yYgpfiY-bz8PDdF8m87HjTV0JbvvB-qdJMmdQFmtGCPL7Tz9uV8sezqID1b8-f9b64G51yKqM7TAqOstzynm52t7aRsKceNejcbp1xQHMaHcdzJ86qjhtaMrmSFpFur_Y9qQDUeUey1TDEZrJEkYmkbrfVf7w7eNBlGxr3sH9AF1XV64cpAl5lFly17tPlzeAut23UL7hu83UYtUW-gzX4NkDpZ4KdYZxLrEM0GuvHOJmxsom8NGjGIGV9AI7ZoxCOJGzTiqsYejT-_fp9ii8PnuI8bFGKDQtPWo1AP5E8cCu-gT3u7hy9eBXb3j6Cg3XAWcBaJSIhI2aAJTDSMU1HGRcTisqAlJbTMJeGcJCTiqaSyEN0CLspQwCpZShneRe16VIv7CIPSIVT2CsIiRmNR5pRLSeMiKfMoDkOyhbruz88KS42vdmgZZi4H8jgDeWVKXlk3yUBeW-iZbzI2vDBX3UycRDP380FFZwC-qxpR38haw8bK_V2zxw4yGWgKFf7jtRjNp5lyHsQxLAfhnnsGS_7RQxrGaueI7X950gfoZvO2PkTt2WQuHqHrxemsmk520LVkkO7Yd-MX6GXxLw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neurogenic+and+anti-inflammatory+effects+of+probiotics+in+Parkinson%E2%80%99s+disease%3A+A+systematic+review+of+preclinical+and+clinical+evidence&rft.jtitle=Brain%2C+behavior%2C+and+immunity&rft.au=Leta%2C+Valentina&rft.au=Ray+Chaudhuri%2C+K.&rft.au=Milner%2C+Oliver&rft.au=Chung-Faye%2C+Guy&rft.date=2021-11-01&rft.pub=Elsevier+Inc&rft.issn=0889-1591&rft.volume=98&rft.spage=59&rft.epage=73&rft_id=info:doi/10.1016%2Fj.bbi.2021.07.026&rft.externalDocID=S0889159121002907 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0889-1591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0889-1591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0889-1591&client=summon |